Key Takeaway
If you use any compounded injectable medication) whether it's semaglutide, tirzepatide, or a peptide like BPC-157 (the safety of that medication depends heavily on USP 797 sterile compounding standards.
If you use any compounded injectable medication) whether it's semaglutide, tirzepatide, or a peptide like BPC-157 (the safety of that medication depends heavily on USP 797 sterile compounding standards. This chapter of the United States Pharmacopeia sets the rules for how pharmacies must prepare medications that go into your body via injection.
Key Takeaways: - The Basics of USP 797 - Cleanroom Requirements and Why They Matter - Beyond-Use Dating: How Long Is Your Medication Safe - Learn how usp 797 protects you
Here's what USP 797 covers and why it should matter to you.
The Basics of USP 797
USP 797 is a set of enforceable standards published by the United States Pharmacopeia. It applies to every pharmacy, hospital, and facility that prepares compounded sterile preparations (CSPs)) which includes all injectable medications.
The standard was first published in 2004 and has been revised several times since. Its purpose is simple: prevent harm from contaminated, improperly prepared, or degraded sterile medications.
USP 797 covers three main areas:
Environmental controls. Where sterile compounding happens matters. The standard requires specific cleanroom classifications, air quality standards, temperature and humidity controls, and cleaning protocols. A pharmacy can't compound injectables on a regular countertop.
Personnel requirements. The people who prepare your medications must be trained, tested, and retrained regularly. USP 797 requires garbing procedures (sterile gowns, gloves, masks), hand hygiene protocols, and competency testing through media-fill tests.
Preparation and testing. The standard dictates how medications must be prepared, what quality tests must be performed, and how long a compounded sterile preparation can be used before it expires (beyond-use dating).
"GLP-1 receptor agonists represent the most significant advance in obesity pharmacotherapy in decades. For the first time, we have medications that produce weight loss approaching what was previously only achievable through bariatric surgery.", Dr. Robert Kushner, MD, Northwestern University, speaking at ObesityWeek 2023
When your arrives in a vial ready for injection, USP 797 is the standard that should have governed every step of its preparation.
Cleanroom Requirements and Why They Matter
The environment where sterile compounding happens is one of the most critical factors in medication safety.
View data table
| Category | Clinical Interest Score | Detail |
|---|---|---|
| BPC-157 | 88 | Tissue repair and gut healing |
| TB-500 | 82 | Injury recovery |
| Sermorelin | 78 | Growth hormone support |
| Ipamorelin | 75 | Anti-aging and recovery |
| GHK-Cu | 70 | Skin and tissue repair |
USP 797 requires sterile compounding to take place in ISO-classified cleanrooms. ISO classification refers to the number of airborne particles allowed per cubic meter of air. The cleaner the room, the lower the particle count.
Primary engineering controls (PECs) are the equipment used for actual compounding (usually a laminar airflow workbench or a biological safety cabinet. These must provide ISO Class 5 air quality, meaning extremely low particle counts.
Buffer areas surround the primary engineering controls and must meet ISO Class 7 standards. These areas act as a transition zone between the outside environment and the compounding area.
Ante-areas are where pharmacists and technicians gown up before entering the buffer area. These must meet ISO Class 8 standards.
Air quality is maintained through HEPA filtration systems that remove 99.97% of particles 0.3 microns or larger. Positive air pressure differentials keep contaminated air from flowing into cleaner areas.
Why does this matter to you? Because injectable medications bypass your skin and immune defenses. A single bacterium in a vial can cause a serious infection. The cleanroom requirements exist to minimize that risk as close to zero as possible.
Free Download: Compounding Pharmacy Verification Checklist Want to know if your pharmacy meets USP 797 standards? This checklist helps you ask the right questions about facility quality, testing, and compliance. Get yours free) we'll email it to you instantly. [Email Input] [Download Button]
Beyond-Use Dating: How Long Is Your Medication Safe?
One of the most practical aspects of USP 797 for patients is beyond-use dating (BUD). This tells you how long your compounded medication remains safe and effective after it's been prepared.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Beyond-use dates aren't the same as expiration dates on commercially manufactured drugs. BUDs are typically shorter because compounded medications are prepared in smaller batches without the extensive stability testing that manufacturers perform.
USP 797 assigns BUDs based on several factors:
Risk category. Preparations are categorized by the complexity of the compounding process. Lower-risk preparations done in compliant conditions may receive longer BUDs. Higher-risk preparations get shorter ones.
Storage conditions. Refrigerated preparations typically get longer BUDs than those stored at room temperature. Frozen preparations may get even longer dates.
Sterility testing. Pharmacies that perform sterility testing on their preparations can assign extended BUDs beyond the default limits.
For you as a patient, this means paying attention to the dating on your medication. Don't use a compounded injectable past its beyond-use date. And store it exactly as instructed (usually refrigerated for peptide and GLP-1 medications.
If you're managing a , proper storage and attention to dating is important for both safety and effectiveness.
How USP 797 Protects You
It's worth stepping back to see the big picture. USP 797 exists because contaminated injectable medications have caused serious harm.
The standard creates multiple layers of protection:
Physical barriers (cleanrooms, HEPA filters, sealed vials) keep contaminants away from your medication during preparation.
Human controls (training, gowning, aseptic technique) minimize the contamination risk from the people preparing your medication.
Testing and verification (sterility testing, potency testing, visual inspection) catch problems before the medication reaches you.
Documentation (batch records, environmental monitoring logs, personnel training records) creates accountability and traceability.
No system is perfect. But a pharmacy that follows USP 797 rigorously is giving you the best possible assurance that your injectable medication is safe.
When you use FormBlends, your medications are prepared by licensed 503A pharmacies that follow these standards. to learn more about how your medications are prepared and tested.
You can also explore our if you're preparing peptides that require mixing before injection.
Frequently Asked Questions
Is USP 797 legally enforceable?
USP 797 is enforceable through state boards of pharmacy, which adopt USP standards as part of their regulatory framework. Most states require compliance with USP 797 for pharmacies that perform sterile compounding. Enforcement varies by state.
How do I know if my pharmacy follows USP 797?
Ask directly. A reputable pharmacy will confirm its USP 797 compliance and may share details about its cleanroom classifications, testing protocols, and personnel training program. PCAB-accredited pharmacies have been independently verified for compliance.
What happens if a pharmacy doesn't follow USP 797?
Non-compliance can result in state board enforcement actions including warnings, fines, license suspension, or closure. More non-compliance increases the risk of contaminated or degraded medications, which can cause patient harm.
Does USP 797 apply to all compounding pharmacies?
USP 797 applies to all facilities that prepare compounded sterile preparations, including pharmacies, hospitals, and outsourcing facilities. It doesn't apply to non-sterile compounding (oral capsules, topical creams), which is covered by USP Chapter 795.
How often is USP 797 updated?
The USP periodically revises Chapter 797 based on new science, technology, and safety data. Major revisions can take years to finalize due to the public comment process. Pharmacies must comply with the current enforceable version.
Ready to Take the Next Step?
Your health goals is personal) and you deserve a plan that fits. FormBlends connects you with licensed providers who can evaluate your needs and create a personalized protocol.
Medical References
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Centers for Disease Control and Prevention. Multistate Outbreak of Fungal Meningitis and Other Infections, United States, 2012. MMWR. 2012;61(41):839-842.
- U.S. Food and Drug Administration. Drug Quality and Security Act (DQSA). Public Law 113-54. November 27, 2013.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
The information in this article is intended for educational use only and shouldn't be considered medical advice. Consult a qualified healthcare provider before making any changes to your medication or supplement regimen. FormBlends helps with connections with licensed providers for personalized medical guidance.
Last updated: 2026-03-24
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →